Investigational Therapy LV-101 Reduces Prader-Willi Symptoms in Children, Phase 2 Trial Shows
Results from a Phase 2 clinical trial show that Levo Therapeutics’ lead therapy candidate, LV-101 (intranasal carbetocin), can effectively reduce symptoms of Prader-Willi syndrome (PWS) in children, the company announced. The investigational therapy was found to decrease the patients’ uncontrolled urge for food and excessive eating, with a…